Efficacy and safety of tumor necrosis factor-α inhibitors and mesenchymal stem cells in the treatment of fistulizing Crohn's disease: a systematic review and network meta-analysis
In brief
Stem cells raised fistula remission odds fivefold versus placebo in Crohn's disease
Across 15 trials involving 2,475 patients, mesenchymal stem cells were linked to about five times the odds of fistula remission versus placebo; anti-TNF drugs also improved remission. Indirect comparisons did not show a significant healing advantage for stem cells over anti-TNF drugs, which performed better for overall clinical remission. Neither treatment showed significantly more adverse events or infections than placebo, but head-to-head trials are lacking.
- Journal
- Frontiers in immunology (Q1)
- Published
- 11 September 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Xue-Min Chen, Li-Chun Han, Bing Han, Jianing Lin, Liyan Chen, Liumei Yan, et al.
- PMID
- 42798531
- DOI
- 10.3389/fimmu.2026.1929235
Why clinicians should know about it
- Picked for Gastroenterology (paper of the day, 29 September 2026): Network meta‑analysis of anti‑TNF vs MSCs for fistulizing Crohn's
Abstract
BACKGROUND: Tumor necrosis factor-α inhibitors (anti-TNF-α) and mesenchymal stem cells (MSCs) have been proven to be effective for Perianal fistulizing Crohn's disease (PFCD). However, no head-to-head clinical trials have directly comparing these two therapies. Therefore, using a network meta-analysis and systematic review, we evaluated the efficacy and safety of anti-TNF-α and MSCs in PFCD patients. METHODS: We included randomized controlled trials (RCTs) evaluating anti-TNF-α or MSCs against placebo (PBO) in PFCD patients. The primary efficacy outcomes were fistula remission and fistula response. The secondary outcome was clinical remission. Safety outcomes comprised adverse events and infections. Effect sizes were reported as odds ratios (ORs) with 95% credible intervals (CrIs). Treatment rankings were determined using the surface under the cumulative ranking curve (SUCRA). RESULTS: A total of 15 RCTs involving 2, 475 patients were included. Compared with PBO, MSCs significantly improved fistula remission (OR = 5.33, 95% CrI: 2.19-19.03) and fistula response (OR = 4.76, 95% CrI: 1.78-20.37). Anti-TNF-α also significantly increased fistula remission rates (OR = 2.19, 95% CrI: 1.01-4.54). SUCRA rankings placed MSCs first for both fistula remission (SUCRA = 0.97) and fistula response (SUCRA = 0.967). For clinical remission, anti-TNF-α demonstrated superior efficacy (OR = 2.41, 95% CrI: 1.30-5.03) compared with MSCs (OR = 1.71, 95% CrI: 0.69-5.57) and PBO. Indirect comparisons revealed a non-significant trend favoring MSCs over anti-TNF-α for fistula remission (OR = 2.44) and fistula response (OR = 2.55). Neither treatment showed statistically significant differences in adverse events or infections versus PBO, indicating favorable safety profiles for both. CONCLUSION: In indirect comparisons, MSCs showed a numerically greater but not statistically significant effect on fistula healing compared with anti-TNF-α, whereas anti-TNF-α was superior for clinical remission. Both treatments were generally safe. Given the indirect nature of these comparisons, direct head-to-head trials are needed to establish their comparative efficacy. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD42021283052.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.